View Past PerformanceCompass Therapeutics バランスシートの健全性財務の健全性 基準チェック /56Compass Therapeuticsの総株主資本は$196.8M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$219.6Mと$22.8Mです。主要情報0%負債資本比率US$0負債インタレスト・カバレッジ・レシオn/a現金US$208.91mエクイティUS$196.79m負債合計US$22.80m総資産US$219.59m財務の健全性に関する最新情報We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business GrowthSep 28We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business GrowthJun 05We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash WiselyFeb 13Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In GrowthSep 20すべての更新を表示Recent updatesCompass Therapeutics Announces Statistically Significant Benefit of Tovecimig in Companion-002 StudyApr 29New minor risk - Profitability Apr 28Forecast to breakeven in 2028 Apr 28New minor risk - Profitability Apr 27Forecast to breakeven in 2028 Apr 26New major risk - Shareholder dilution Mar 08No longer forecast to breakeven Mar 05Compass Therapeutics: Exciting Clinical Updates Inbound For 2026 Jan 20Compass Therapeutics, Inc. Announces Executive Appointments, Effective as of January 1, 2026Jan 06Compass Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Dec 31Forecast to breakeven in 2028 Dec 31New minor risk - Profitability Nov 09New minor risk - Share price stability Aug 19New minor risk - Shareholder dilution Aug 14Compass Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $119.999329 million.Aug 14Compass Therapeutics, Inc. has filed a Follow-on Equity Offering.Aug 13New minor risk - Profitability May 11Compass Therapeutics, Inc., Annual General Meeting, Jun 11, 2025Apr 30Compass Therapeutics, Inc. Presents Data on Enhanced Efficacy of Ctx-471 in Combination with Tovecimig in Checkpoint-Refractory Models At the American Association for Cancer Research Annual MeetingApr 28Compass Therapeutics, Inc. Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract CancerApr 21Price target increased by 15% to US$13.10 Apr 04Compass Therapeutics, Inc. Announces Top-Line Data on the Primary Efficacy Endpoint for COMPANION-002Apr 01Compass Therapeutics, Inc. Announces 2024 Accomplishments and 2025 Pipeline UpdatesMar 01No longer forecast to breakeven Feb 27New major risk - Share price stability Feb 22Compass Therapeutics, Inc. Announces Advancement of A New Drug CandidateJan 08Forecast to breakeven in 2027 Dec 31Price target increased by 45% to US$11.00 Dec 26Compass Therapeutics, Inc. Appoints Barry Shin as Chief Financial OfficerDec 11Consensus revenue estimates increase by 49% Nov 19New minor risk - Profitability Nov 15We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business GrowthSep 28Consensus revenue estimates increase by 32% Sep 17Price target decreased by 13% to US$8.00 Aug 13Compass Therapeutics, Inc.(NasdaqCM:CMPX) dropped from Russell 2500 Growth IndexJul 03We Think Compass Therapeutics (NASDAQ:CMPX) Can Afford To Drive Business GrowthJun 05Compass Therapeutics, Inc. Announces Management ChangesMay 29+ 1 more updateCompass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024May 24Compass Therapeutics, Inc., Annual General Meeting, Jun 13, 2024Apr 28Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously TreatedApr 26Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid TumorsApr 16New minor risk - Shareholder dilution Mar 22We're Hopeful That Compass Therapeutics (NASDAQ:CMPX) Will Use Its Cash WiselyFeb 13Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024Jan 07Compass Therapeutics, Inc. Announces Executive Changes, Effective January 9, 2024Jan 06Companies Like Compass Therapeutics (NASDAQ:CMPX) Are In A Position To Invest In GrowthSep 20Ankyra Therapeutics Names Robert V. Tighe as Chief Scientific OfficerAug 17New major risk - Revenue and earnings growth Aug 06New minor risk - Share price stability Jul 09Co-Founder recently bought US$80k worth of stock Mar 03Co-Founder recently bought US$77k worth of stock Feb 19Compass Therapeutics, Inc. Appoints David Wurzer as Class III Director, Member and Chairman of the Audit CommitteeFeb 12Price target increased to US$9.46 Jan 19Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal CancerJan 07Compass Therapeutics, Inc. Announces That the First Patient Has Been Dosed in the Phase 1B Study of CTX-471 in Combination with Keytruda®, Merck’S Anti-PD-1 TherapyDec 02+ 1 more updatePresident & COO recently sold US$97k worth of stock Nov 24Price target increased to US$9.67 Nov 16High number of new and inexperienced directors Nov 16Compass Therapeutics, Inc. announced that it expects to receive $80.25 million in funding from a group of investorsNov 04+ 1 more updateCompass Therapeutics, Merck ink collaboration deal for early-stage cancer trial Oct 11High number of new and inexperienced directors Sep 15Compass Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board of Directors, Effective August 31, 2022Aug 20High number of new and inexperienced directors Jun 01Co-Founder recently bought US$61k worth of stock May 28Co-Founder recently bought US$50k worth of stock May 11Compass Therapeutics, Inc. Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract CancersMay 05High number of new and inexperienced directors May 02Price target decreased to US$8.86 Apr 27Compass Therapeutics Announces Management AppointmentsApr 27Compass Therapeutics, Inc. Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual MeetingApr 09Compass Therapeutics, Inc. Announces Resignation of Brett Kaplan of the Board of DirectorsFeb 27Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)Jan 22High number of new and inexperienced directors Nov 02Compass Therapeutics, Inc. (OTCPK:CMPX) entered into a definitive merger agreement to acquire TRIGR Therapeutics, Inc. for $45.2 million.May 14財務状況分析短期負債: CMPXの 短期資産 ( $209.8M ) が 短期負債 ( $14.0M ) を超えています。長期負債: CMPXの短期資産 ( $209.8M ) が 長期負債 ( $8.8M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: CMPXは負債がありません。負債の削減: CMPX負債比率が23.4%であった 5 年前と比べて負債がありません。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: CMPXは、現在の フリーキャッシュフロー に基づき、3 年以上にわたって十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: CMPXの フリー キャッシュ フロー が過去のレートに基づいて増加または減少し続ける場合、十分な キャッシュ ランウェイ があるかどうかを判断するためのデータが不十分です。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/30 14:54終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Compass Therapeutics, Inc. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。24 アナリスト機関Aydin HuseynovBenchmark CompanyMayank MamtaniB. Riley Securities, Inc.Justin WalshB. Riley Securities, Inc.21 その他のアナリストを表示
Compass Therapeutics Announces Statistically Significant Benefit of Tovecimig in Companion-002 StudyApr 29
Compass Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.Dec 31
Compass Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $119.999329 million.Aug 14
Compass Therapeutics, Inc. Presents Data on Enhanced Efficacy of Ctx-471 in Combination with Tovecimig in Checkpoint-Refractory Models At the American Association for Cancer Research Annual MeetingApr 28
Compass Therapeutics, Inc. Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract CancerApr 21
Compass Therapeutics, Inc. Announces Top-Line Data on the Primary Efficacy Endpoint for COMPANION-002Apr 01
Compass Therapeutics to Present Phase 1 Data for CTX-471, a Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024May 24
Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously TreatedApr 26
Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid TumorsApr 16
Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024Jan 07
Compass Therapeutics, Inc. Appoints David Wurzer as Class III Director, Member and Chairman of the Audit CommitteeFeb 12
Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal CancerJan 07
Compass Therapeutics, Inc. Announces That the First Patient Has Been Dosed in the Phase 1B Study of CTX-471 in Combination with Keytruda®, Merck’S Anti-PD-1 TherapyDec 02+ 1 more update
Compass Therapeutics, Inc. announced that it expects to receive $80.25 million in funding from a group of investorsNov 04+ 1 more update
Compass Therapeutics, Inc. Announces Resignation of Stephen Squinto as Member of the Board of Directors, Effective August 31, 2022Aug 20
Compass Therapeutics, Inc. Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract CancersMay 05
Compass Therapeutics, Inc. Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual MeetingApr 09
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)Jan 22
Compass Therapeutics, Inc. (OTCPK:CMPX) entered into a definitive merger agreement to acquire TRIGR Therapeutics, Inc. for $45.2 million.May 14
